Abstract
We present an age-stratified SEIR-type model of the Norwegian population, which is extended to include the effects of broad types of Non-Pharmaceutical Interventions (NPIs) like general lockdown-policies, contact tracing and quarantine and border control. The model can be used to explore the spread of a new virus with given virulence and transmissibility, and to assess the main costs of the disease and the NPIs in terms of lost health and welfare as well as economic losses. We define the optimal strategy as the intervention policy which minimizes the total costs from the pandemic, including health, economic and other welfare effects. We find that the optimal policy typically is a “bang-bang-strategy”, where costly interventions are either so strict that the pandemic is suppressed to a low level, or they are not used at all. Strict interventions may be used to stop the disease at the herd immunity level (i.e prevent pandemic overshoot), while mitigation policies aimed at merely slowing the spread of the pandemic are not optimal in our baseline simulations. We explore how the optimal strategy depends on the properties of the virus, healthcare capacity, intervention costs, population behavior and other relevant variables. These results are informative for decisions regarding costly investments and interventions. In addition, we explore the consequences of policy errors and delays, providing guidance for decision making in the uncertain early stages of a new pandemic.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Steinar Holden has received financial support from the Research Council of Norway, grant no 324615.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All computer code used for processing and data analysis is available at: https://github.com/folkehelseinstituttet/covid19_economic_evaluation
https://github.com/folkehelseinstituttet/covid19_economic_evaluation